A Phase 3 trial of SNF472 for the Treatment of Peripheral Arterial Disease
Latest Information Update: 02 Dec 2021
At a glance
- Drugs Hexasodium fytate (Primary)
- Indications Peripheral arterial disorders
- Focus Therapeutic Use
- Sponsors Laboratoris Sanifit
Most Recent Events
- 22 Nov 2021 According to a Sanifit media release, trial is expected to commence in 2022.
- 26 Apr 2021 New trial record